The global anti-counterfeit pharmaceuticals and cosmetics packaging market is expected to grow over the next six years owing to increasing rules and regulations and government initiatives to protect consumers from the use of harmful products.
Personal care and cosmetic products are the top priority targets for counterfeiters. Counterfeiting is more relevant in high-volume and low-value markets. The premium beauty products and personal care products have now become daily skincare products, which are available widely in the local market. This has caused more counterfeiting of such consumables posing a need to design some stringent rules.
The International Trade Association (INTA) supports Anti-counterfeiting Trade Agreement (ACTA), a guideline for the enforcement of trademark anti-counterfeiting. In September 2012, Japan was the first to sign this agreement. INTA along with International Chamber of Commerce’s Business Action has formed Business Response Group (BRG) to Stop Counterfeiting (BASCAP) so that national and international industries can comment and give suggestions for ACTA.
Pharmaceutical is not a centralized sector and, hence many small-scale players have started managing their own supply chains. Increasing counterfeiting has now led to track-and-trace technologies, which secure the original product verifying them with multi-layered authentic technologies.
Although premium product companies can afford trace-and-track technologies such as e-Pedigree and Radio Frequency Identification System (RFID), economic product companies use conventional methods such as holograms, dyes, and inks.
The anti-counterfeiting market is segmented into technology, application, and region. Technologies include authentic packaging technologies such as ink and dyes, security inks, holograms, watermarks, and taggants. Other type of technology is called track-and-trace technology, which is the bar code technology and RFID technology. The RFID technology leads the market in the technology sector. This is attributed to the efficiency and effectiveness provided by it in tracking high-value products.
The application segment of the anti-counterfeit pharmaceuticals and cosmetics packaging industry includes food packaging, pharmaceutical packaging, over the counter drugs, and prescription drugs. Increasing healthcare expenditure and government initiatives are expected to propel pharmaceutical packaging segment growth over the forecast period.
In September 2015, 4th Annual Pharma Anti-Counterfeiting is expected to take place in London. The key points to be discussed are government policies in the EU and the U.S. for pharma anti-counterfeiting and product securities, developing strategies for using the latest technology throughout supply chain, including anti-counterfeiting in business plan, and many more topics to enhance knowledge and increase awareness among the industry players.
Geographical segments include North America, Europe Asia Pacific, Latin America, and MEA. In 2014, North America dominated the industry owing to the maximum pharmaceutical product innovations, a broad consumer durable market, and expensive healthcare costs. The pharmaceutical and cosmetic industry is projected to have maximum counterfeiting in Europe, therefore, making this region a lucrative regional segment.
Asia Pacific is expected to be the fastest growing market owing to the continuous support by the pharma companies organizing awareness campaigns and also rising level of awareness about authentic pharmaceutical drugs. In August 2015, Alibaba, a Chinese online retailer, offered counterfeit reporting in English. This enabled foreign customers to file complaints and place requests on its Tmall and Taobao e-commerce sight.
Major companies governing the anti-counterfeiting industry are Alien Technology Corp., Flint Group, InkSure Technologies, Honeywell, AlpVision, Sicapa, Avery Dennison, Authentix Inc., Impinj Incorporation, and Zebra Technologies.
In January 2014, Alien Technology introduced Glint ALN-9715, a footprint for tagging cosmetics, jewelry, and other metal-coated products. The Glint tag includes UHF antenna, which tags till 3 feet. In April 2014, Alien introduced two UHF passive RFID tags, Wonder Dog ALN-9768 and Higgs 4 IC near-field inlay.
Flint Group, headquartered in the U.S., inaugurated its new plant in India in January 2013. This enabled the company to reduce the delivery time and get closer to customers, especially in North and West India.
In October 2012, InkSure technology, which specializes in machine-readable anti-counterfeiting solutions, introduced high-security taggants approved by the FDA for direct contact foods. They have wide applications in protecting tobacco and alcohol products, keeping harmful products away from consumer use.
Fingerprint, a breakthrough product of AlpVision, is used to track mass-produced molding objects. In May 2012, Nolato Medical and AlpVision announced a partnership in order to protect primary pharmaceutical packaging and medical devices.
The strategic initiatives by various industry players to expand their industry share include complying with the agreements such as INTA and collaborations between manufacturers to provide cost-efficiency and economy of scale. All these factors are expected to enhance anti-counterfeit pharmaceuticals and cosmetics packaging market growth over the forecast period.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.